Summary of BIOGEN IDEC INC.

Quotes & Info

Enter Symbol(s):
e.g. YHOO, ^DJI

Symbol Lookup | Financial Search

BIIB > SEC Filings for BIIB > Form 8-K on 15-Sep-2009

All Recent SEC Filings

Show all filings for BIOGEN IDEC INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for BIOGEN IDEC INC.

15-Sep-2009

Other Events

Item 8.01 Other Events
Biogen Idec has been issued U.S. patent #7,588,755 for the use of beta interferon for immunomodulation or treating a viral condition, viral disease, cancers or tumors. This patent covers the treatment of multiple sclerosis with AVONEX® (Interferon beta-1a), which is Biogen Idec's brand of recombinant beta interferon. This patent will expire in September 2026.

Add BIIB to Portfolio

Set Alert

Email to a Friend

Get SEC Filings for Another Symbol: Symbol Lookup

Quotes & Info for BIIB - All Recent SEC Filings

Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.